Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GX15-070MS · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| GX15-070MS | EXPERIMENTAL | GX15-070MS at various doses and schedules |
| Name | Type | Description |
|---|---|---|
| GX15-070MS | DRUG | A 60-minute or 3-hour IV infusion every 2-3 weeks. |
Inclusion Criteria: * Histologically or cytologically confirmed B-CLL * Previous standard systemic chemotherapy, including fludarabine. There are no limitations on additional, allowable type and amount of prior therapy. Acute toxicities from prior therapy must have resolved to ≤Grade 1 * Age ≥18 ye...
GX15-070MS is an investigational small molecule being studied for the treatment of chronic lymphocytic leukemia (CLL). It is in Phase 1 clinical development and has been evaluated in a completed clinical trial for patients with untreated CLL.
GX15-070MS is being developed by Teva Pharmaceutical Industries Limited, a company listed on the stock exchange under the ticker TEVA. The drug is currently in Phase 1 clinical development for chronic lymphocytic leukemia.
GX15-070MS is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1/II study of the drug in chronic lymphocytic leukemia has been completed.
GX15-070MS has been studied in clinical trial NCT00600964, titled 'A Phase I/II Study of GX15-070MS in Untreated CLL'. This trial was completed and enrolled 26 participants with chronic lymphocytic leukemia in the United States and Canada.
GX15-070MS is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for chronic lymphocytic leukemia. The drug has completed one clinical trial but remains under investigation and has not been approved for any use.